SMARCA5

Across TCGA pan-cancer cohorts, SMARCA5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMARCA5 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SMARCA5 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SMARCA5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where SMARCA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.380	1.000	.008	45	view →
PDAC	OS	Tertile	II,III,IV	0.729	0.916	<.001	20	view →
CCRCC	OS	Tertile	All	0.851	0.975	.019	12	view →
LSCC	OS	Median	All	1.000	0.937	.013	10	view →
UCEC	DFS	Tertile	All	0.866	0.973	.021	2	view →
GBM	OS	Tertile	All	0.520	0.296	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMARCA5–HNSC (OS)

Open the HNSC breakdown →